A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.

[1]  D. Zheng,et al.  Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade , 2013, Cell.

[2]  H. Scher,et al.  Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D). , 2013 .

[3]  K. Ovaska,et al.  FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. , 2013, Cancer research.

[4]  F. Saad,et al.  Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[6]  J. Bono,et al.  Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer , 2012, Molecular and Cellular Endocrinology.

[7]  I. McEwan,et al.  Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. , 2012, Cancer research.

[8]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[9]  T. Powles,et al.  A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol , 2011, British Journal of Cancer.

[10]  J. D. de Bono,et al.  Abiraterone acetate is well tolerated without concomitant use of corticosteroids. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Fosså,et al.  Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. , 2007, European urology.

[12]  Alan Horwich,et al.  Efficacy of low‐dose dexamethasone in castration‐refractory prostate cancer , 2007, BJU international.

[13]  K. Kihara,et al.  Glucocorticoids Suppress Tumor Angiogenesis and In vivo Growth of Prostate Cancer Cells , 2006, Clinical Cancer Research.

[14]  L. Collette,et al.  Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer , 2005, Oncology.

[15]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[16]  E. Small,et al.  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Dakhil,et al.  Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. , 2002, The Journal of urology.

[18]  Y. Jo,et al.  Prostate-Specific Antigen Levels and Prognosis in Patients with Hormone-Refractory Prostate Cancer Treated with Low-Dose Dexamethasone , 2002, Urologia Internationalis.

[19]  N Nonomura,et al.  Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. , 2001, Journal of the National Cancer Institute.

[20]  H. Kumon,et al.  Treatment of androgen‐independent prostate cancer with dexamethasone: A prospective study in stage D2 patients , 2001, International journal of urology : official journal of the Japanese Urological Association.

[21]  T. Miki,et al.  Low doses of oral dexamethasone for hormone‐refractory prostate carcinoma , 2000, Cancer.

[22]  Donna M. Peehl,et al.  Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor , 2000, Nature Medicine.

[23]  M. Benson,et al.  Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. , 2000, The Journal of urology.

[24]  D. Osoba,et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Buckner,et al.  Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone‐refractory metastatic prostate carcinoma , 1995, Cancer.

[26]  I. Tannock,et al.  Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Dorff,et al.  Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  L. Collette,et al.  Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Vassilopoulou-sellin,et al.  Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer. , 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[30]  D. Peehl,et al.  Erratum: Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor (Nature Medicine (2000) 6 (703-706)) , 2000 .